Skip to main content
Search
Search
Advanced Search
Skip main navigation
Open access
Research Article
15 December 2023

Treatment patterns and economic burden of bacterial vaginosis among commercially insured women in the USA

Authors: Eren Watkins, Clifton M Chow, Melissa Lingohr-Smith, Jay Lin https://orcid.org/0000-0002-6376-8469 [email protected], Candice Yong, Krishna Tangirala, Kevin Collins, James Li, Roy Brooks, and Jennifer AmicoAuthor Info & Affiliations
Volume 13, Number 1
https://doi.org/10.57264/cer-2023-0079
PDFFormats

Abstract

Aim: Bacterial vaginosis (BV) is a common vaginal dysbiosis associated with adverse clinical sequelae, most notably, increased risk of sexually transmitted infections (STIs). The aims of this study were to estimate the frequency of BV recurrence, treatment patterns, other gynecological (GYN) conditions, and the associated healthcare resource utilization (HCRU) and costs among commercially insured patients in the USA. Patients & methods: Female patients aged 12–49 years with an incident vaginitis diagnosis and ≥1 pharmacy claim for a BV medication (fungal treatment only excluded) were selected from the Merative™ MarketScan commercial database (2017–2020). During a minimum 12-month follow-up, additional treatment courses, treatment patterns, frequency of other GYN conditions, and HCRU and costs were assessed. Generalized linear models were used to identify baseline predictors of total all-cause healthcare costs and number of treatment courses. Results: The study population included 140,826 patients (mean age: 31.5 years) with an incident vaginitis diagnosis and ≥1 BV medication claim. During the follow-up, 64.2% had 1 treatment course, 22.0% had 2, 8.1% had 3, and 5.8% had ≥4; 35.8% had a BV recurrence (≥2 BV medication claims). The most commonly prescribed BV medication was oral metronidazole (73.6%). Approximately 12% (n = 16,619) of patients had a new diagnosis of another GYN condition in the follow-up; 8.2% had a new STI, which were more common among patients with ≥4 treatment courses (12.9%). During follow-up, total all-cause healthcare costs averaged $8987 per patient per year (PPPY) of which $470 was BV-related. BV-related healthcare costs increased from $403 PPPY among those with 1 treatment course to $806 PPPY among those with ≥4 with nearly half the costs attributed to outpatient office visits. Conclusion: BV recurrence among this population represented a substantial clinical and healthcare economic burden warranting improvements in women's healthcare.

Plain language summary

What was the aim of this research?

The aims of this study were to estimate the frequency of bacterial vaginosis (BV) recurrence, treatment patterns, rates of other gynecological (GYN) conditions, and the associated healthcare resource utilization (HCRU) and costs among commercially insured patients in the USA.

How was the research carried out?

Female patients aged 12–49 years with an incident vaginitis diagnosis and at least 1 pharmacy claim for a BV medication were selected from the MarketScan commercial database (2017–2020). During a minimum 12-month follow-up, additional treatment courses, treatment patterns, frequency of other GYN conditions and HCRU and costs were assessed.

What were the results?

Among our study population of 140,826 commercially insured patients 12–49 years of age who were diagnosed with incident vaginitis and were prescribed at least one BV medication, 36% had BV recurrence during the follow-up period (mean: 28.5 months). Approximately 12% of patients had a new diagnosis of a GYN condition in the follow-up; 8.2% had a new sexually transmitted infection, which were more common among patients with ≥4 treatment courses (12.9%). During follow-up, total all-cause healthcare costs averaged $8987 per patient per year (PPPY) of which $470 was BV-related. BV-related healthcare costs increased from $403 PPPY among those with 1 treatment course to $806 PPPY among those with ≥4 with nearly half the costs attributed to outpatient office visits.

What do the results of the study mean?

BV recurrence among this population represented a substantial clinical and healthcare economic burden warranting improvements in women's healthcare.

Supplementary Material

File (supplementary data.docx)

References

Papers of special note have been highlighted as: • of interest; •• of considerable interest
1.
Morris M, Nicoll A, Simms I, Wilson J, Catchpole M. Bacterial vaginosis: a public health review. BJOG 108(5), 439–450 (2001).
PubMed
Google Scholar
2.
Muzny CA, Balkus J, Mitchell C et al. Diagnosis and management of bacterial vaginosis: summary of evidence reviewed for the 2021 Centers for Disease Control and Prevention sexually transmitted infections treatment guidelines. Clin. Infect. Dis. 74(Suppl. 2), S144–S151 (2022).
PubMed
Google Scholar
•• Presents Centers for Disease Control and Prevention (CDC) recommended bacterial vaginosis (BV) treatment guidelines.
3.
Paladine HL, Desai U. Vaginitis: diagnosis and treatment. Am. Fam. Physician 97(5), 321–329 (2018).
PubMed
Google Scholar
4.
Allsworth JE, Peipert JF. Prevalence of bacterial vaginosis: 2001–2004 National Health and Nutrition Examination Survey data. Obstet. Gynecol. 109(1), 114–120 (2007).
PubMed
Google Scholar
5.
Mollin A, Katta M, Sobel JD, Akins RA. Association of key species of vaginal bacteria of recurrent bacterial vaginosis patients before and after oral metronidazole therapy with short- and long-term clinical outcomes. PLOS ONE 17(7), e0272012 (2022).
PubMed
Google Scholar
6.
Salazar AS, Nogueira NF, Rodriguez VJ et al. A syndemic approach to explore factors associated with bacterial vaginosis. AIDS Behav. 26(9), 3110–3118 (2022).
PubMed
Google Scholar
7.
Muzny CA, Harbison HS, Austin EL et al. Sexually transmitted infection risk among women is not fully explained by partner numbers. South Med. J. 110(3), 161–167 (2017).
PubMed
Google Scholar
8.
Bradshaw CS, Sobel JD. Current treatment of bacterial vaginosis – limitations and need for innovation. J. Infect. Dis. 214(Suppl. 1), S14–S20 (2016).
PubMed
Google Scholar
•• Review of current BV treatment.
9.
Bradshaw CS, Morton AN, Hocking J et al. High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. J. Infect. Dis. 193(11), 1478–1486 (2006).
PubMed
Google Scholar
10.
Oduyebo OO, Anorlu RI, Ogunsola FT. The effects of antimicrobial therapy on bacterial vaginosis in non-pregnant women. Cochrane Database Syst. Rev. 8(3), CD006055 (2009).
Google Scholar
11.
Sobel JD, Ferris D, Schwebke J et al. Suppressive antibacterial therapy with 0.75% metronidazole vaginal gel to prevent recurrent bacterial vaginosis. Am. J. Obstet. Gynecol. 194(5), 1283–1289 (2006).
PubMed
Google Scholar
12.
Workowski KA, Bolan GA. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm. Rep. 64(RR-03), 1–137 (2015).
PubMed
Google Scholar
13.
Faught BM, Reyes. Characterization and treatment of recurrent bacterial vaginosis. J. Womens Health (Larchmt). 28(9), 1218–1226 (2019).
PubMed
Google Scholar
•• Presents CDC recommended BV treatment guidelines.
14.
Landlinger C, Oberbauer V, Tisakova LP et al. Preclinical data on the Gardnerella-specific endolysin PM-477 indicate its potential to improve the treatment of bacterial vaginosis through enhanced biofilm removal and avoidance of resistance. Antimicrob. Agents Chemother. 66(5), e0231921 (2022).
PubMed
Google Scholar
15.
Kong AM, Jenkins D, Troeger K, Kim G, London RS. Diagnostic testing of vaginitis: improving the value of care. Popul. Health Manag. 24(4), 515–524 (2021).
PubMed
Google Scholar
• Study of costs associated with BV.
16.
Troeger KA, Thiel ER, London RS. Optimizing vaginitis diagnosis to reduce health care costs in nonpregnant women utilizing molecular diagnostics. Popul. Health Manag. 25(4), 449–454 (2022).
PubMed
Google Scholar
• Study of costs associated with BV.
17.
Centers for Disease Control and Prevention. Bacterial vaginosis – CDC fact sheet. (2023). www.cdc.gov/std/bv/stdfact-bacterial-vaginosis.htm
Google Scholar
18.
Hillier SL, Austin M, Macio I, Meyn LA, Badway D, Beigi R. Diagnosis and treatment of vaginal discharge syndromes in community practice settings. Clin. Infect. Dis. 72(9), 1538–1543 (2021).
PubMed
Google Scholar
19.
Sobel JD, Kaur N, Woznicki NA et al. Conventional oral and secondary high dose vaginal metronidazole therapy for recurrent bacterial vaginosis: clinical outcomes, impacts of sex and menses. Infect. Drug Resist. 12, 2297–2307 (2019).
PubMed
Google Scholar
20.
Sobel JD, Kaur N, Woznicki NA et al. Prognostic indicators of recurrence of bacterial vaginosis. J. Clin. Microbiol. 57(5), e00227–19 (2019).
PubMed
Google Scholar
21.
Armstrong E, Hemmerling A, Joag V et al. Treatment success following standard antibiotic treatment for bacterial vaginosis is not associated with pretreatment genital immune or microbial parameters. Open Forum Infect. Dis. 10(1), ofad007 (2023).
PubMed
Google Scholar
22.
Kreisel K, Spicknall IH, Gargano JW et al. Sexually transmitted infections among US women and men: prevalence and incidence estimates, 2018. Sex. Transm. Dis. 48(4), 208–214 (2021).
PubMed
Google Scholar
23.
Centers for Disease Control and Prevention. Reported STDs reach all-time high for 6th consecutive year. (2023). www.cdc.gov/media/releases/2022/p0412-STD-Increase.html
Google Scholar
24.
Van Gerwen OT, Muzny CA, Marrazzo JM. Sexually transmitted infections and female reproductive health. Nat. Microbiol. 7(8), 1116–1126 (2022).
PubMed
Google Scholar
25.
Brotman RM, Klebanoff MA, Nansel TR et al. Bacterial vaginosis assessed by Gram stain and diminished colonization resistance to incident gonococcal, chlamydial, and trichomonal genital infection. J. Infect. Dis. 202(120), 1907–1915 (2010).
PubMed
Google Scholar
26.
Shipitsyna E, Khusnutdinova T, Budilovskaya O et al. Bacterial vaginosis-associated vaginal microbiota is an age-independent risk factor for Chlamydia trachomatis, Mycoplasma genitalium and Trichomonas vaginalis infections in low-risk women, St. Petersburg, Russia. Eur. J. Clin. Microbiol. Infect. Dis. 39(7), 1221–1230 (2020).
PubMed
Google Scholar
27.
Wiesenfeld HC, Hillier SL, Krohn MA, Landers DV, Sweet RL. Bacterial vaginosis is a strong predictor of Neisseria gonorrhoeae and Chlamydia trachomatis infection. Clin. Infect. Dis. 36(5), 663–685 (2003).
PubMed
Google Scholar
28.
US Department of Health and Human Services. STI national strategic plan overview. (2023). www.hhs.gov/programs/topic-sites/sexually-transmitted-infections/plan-overview/index.html
Google Scholar
29.
Brown H, Drexler M. Improving the diagnosis of vulvovaginitis: perspectives to align practice, guidelines, and awareness. Popul. Health Manag. 23(Suppl. 1), S3–S12 (2020).
PubMed
Google Scholar
•• Covers STI USA national strategic plan.
30.
Ackerman SJ, Knight T, Wahl PM, Cartwright CP. Health care utilization and costs following amplified versus non-amplified molecular probe testing for symptomatic patients with suspected vulvovaginitis: a US commercial payer population. Clinicoecon. Outcomes Res. 11, 179–189 (2019).
PubMed
Google Scholar
31.
Watkins E, Chow C, Lingohr-Smith M et al. Bacterial vaginosis treatment patterns, associated complications, and healthcare economic burden of women with Medicaid coverage in the United States. Ann. Pharmacother. (2023) (Epub ahead of Print).
Crossref
Google Scholar
•• Comparative study among patients with Medicaid coverage.
|